Label Changes for:
Anzemet (dolasetron mesylate)
Changes have been made to the PRECAUTIONS and ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
changes: remove all information for the prevention of postoperative nausea and vomiting based on current guidelines regarding the administration of oral Anzemet prior to surgery in the following sections: